From: The efficacy of L-carnitine in patients with nonalcoholic steatohepatitis and concomitant obesity
Parameter | Group | T0 of treatment | T1 after the start of treatment | T2 after the start of treatment |
---|---|---|---|---|
Fasting glucose, mmol/L | 1 | 5.77 ± 0.13* | 5.63 ± 0.14* | 5.25 ± 0.08** |
2 | 5.81 ± 0.15* | 5.08 ± 0.09**/*** | 4.96 ± 0.05**/*** | |
2-hour postprandial glucose, mmol/L | 1 | 9.01 ± 0.32* | 8.57 ± 0.24* | 7.80 ± 0.14*/** |
2 | 9.05 ± 0.24* | 7.96 ± 0.16* | 7.31 ± 0.10**/*** | |
Insulin, µU/mL | 1 | 23.10 ± 2.41* | 18.86 ± 2.33* | 16.2 ± 1.32* |
2 | 23.15 ± 2.35* | 15.17 ± 1.48*/** | 10.02 ± 0.55**/*** | |
HOMA-IR | 1 | 3.02 ± 0.12* | 2.47 ± 0.18 * | 2.10 ± 0.15*/** |
2 | 3.03 ± 0.14* | 1.82 ± 0.08 */**/*** | 1.29 ± 0.07**/*** |